Lupin Limited’s launch of generic Spiriva (tiotropium bromide) in the US market, shortly after its Q1 results were announced, will be essential for the firm to maintain the exit margins it has predicted for the close of FY2024.
Spiriva Generic Must Deliver To Maintain Exit Margin Estimates At Lupin
Q1 Results Reflect Return To Form After Muted Performance
The performance of its recently-launched Spiriva generic will be crucial for Lupin’s future performance, as it forecasts year-end exit margins in the high teens.
